Children’s National Hospital and NIAID launch large study on long-term impacts of COVID-19 and MIS-C on kids

NEXT STORY
SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041
PREV STORY
Pacific Biosciences Signs Definitive Agreement to Acquire Omniome
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Children’s National Hospital and NIAID launch large study on long-term impacts of COVID-19 and MIS-C on kids

NEXT STORY
SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041
PREV STORY
Pacific Biosciences Signs Definitive Agreement to Acquire Omniome
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

New Kidney360 Publication Highlights CareDx’s AlloSure is Differentiated as the dd-cfDNA Test of Choice

author_avatar
NASDAQ Market News

New Lactation Rooms Added to the ABOG Educational Foundation Test Center

Certifying Exam Candidates and Examiners Provide Positive Feedback About the AccommodationsDallas, Texas, Feb. 05, ...

author_avatar
NASDAQ Market News

SELECTION-studie naar filgotinib bij colitis ulcerosa, gepubliceerd in The Lancet

author_avatar
NASDAQ Market News